Overview

Randomized, Open-Label, Study to Evaluate the Safety and Efficacy of Sofosbuvir Tablet Plus Ribavirin Tablet (Part A) Versus Single Dose (2 Tablets) of EHCV Containing Sofosbuvir, Ribavirin, and Natural Anti-hemolytic (B) in Egyptian Adults With Chr

Status:
Completed

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

Summary

Two Groups of Genotype 4 HCV Patients will participate through open-label randomized Study comparing Sofosbuvir tablet Plus Ribavirin tablet (Part A) versus single Dose (2 tablets) of EHCV containing Sofosbuvir, Ribavirin, and Natural anti-hemolytic (B) evaluating the safety and efficacy for both arms. Sponsor: Wadi El Nil Hospital Study Centers Planned: Approximately 2 sites in Egypt

Phase:

Phase 2/Phase 3

Details

Lead Sponsor:

Egyptian Liver Hospital

Collaborator:

Wadi El Nil Hospital

Treatments:

Ribavirin
Sofosbuvir